Close

Aziyo Biologics (AZYO) Announces Proposed Public Offering of Common Stock

November 30, 2022 4:12 PM EST

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that it has commenced an underwritten public offering, subject to market and other conditions, of shares of its common stock. Aziyo also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock equal to 15% of the shares of common stock to be sold in the offering to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. All shares in the offering are to be sold by Aziyo.

Cantor Fitzgerald & Co. is acting as sole book running manager for the proposed offering.

Aziyo intends to use the net proceeds of the offering to expand its product development and clinical research activities, hire additional sales personnel to coincide with product launches and the remainder to fund working capital and other general corporate purposes.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on August 31, 2022 and declared effective on September 8, 2022. A preliminary prospectus supplement describing the terms of the public offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering may be obtained, when available, by contacting Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th floor, New York, NY 10022; Email: [email protected]. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus and the other documents that Aziyo has filed with the SEC for more complete information about Aziyo and the proposed offering.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings

Related Entities

Cantor Fitzgerald, S3